Thrombosis News and Research

Latest Thrombosis News and Research

Study: Heparin plays a key role in mast cell-driven allergic and inflammatory reactions

Heparin plays a key role in allergic and inflammatory reactions driven by mast cells, scientists from Karolinska Institutet in Sweden shows in an international collaboration involving colleagues from Germany and Switzerland. The study is published in the recent issue of Immunity, and sheds some new light on the biological function of heparin.

25 Feb 2011

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

W. L. Gore & Associates announced the GORE PROPATEN Vascular Graft for hemodialysis access has received CE Mark. Arteriovenous Grafts are used to create a conduit for repeated blood access during hemodialysis, allowing blood to be withdrawn from the body and cleansed when a patient has End Stage Renal Disease, commonly referred to as kidney failure.

22 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

Rare bleeding disorder misdiagnosed

A rare bleeding disorder that can lead to life-threatening bleeding episodes is misdiagnosed in 15 per cent of cases according to findings from a new international research project led by a Queen's professor.

17 Feb 2011

Avesthagen completes development of microalgae based vegetarian DHA omega 3 essential fatty acid

Avesthagen Limited announced completion of a landmark project for the development of AvestaDHA(TM) - a vegetarian source of DHA (docohexanoic acid) omega 3 essential fatty acid based on an innovative approach using naturally occurring microalgae.

17 Feb 2011

FDA grants 510(k) clearance to Venous Health's Vasculaire Compression System in the US

Venous Health Systems, a developer of solutions for treating vascular insufficiency by enhancing blood circulation, today announced that it has received 510 clearance from the Food & Drug Administration to market the Vasculaire Compression System in the United States.

15 Feb 2011

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

AngioDynamics announced today the launch of a new Morpheus® SMART PICC bedside insertion kit and new 5 French Dual Lumen Peripherally Inserted Central Catheter (PICC) as part of the continued growth of its Morpheus SMART PICC line.

14 Feb 2011

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

ThromboGenics NV and co-development partner BioInvent International announce today that the positive TB-402 Phase II trial results, evaluating the product's efficacy and safety for the prevention of venous thromboembolism afterorthopaedic surgery, have been published in the Journal of Thrombosis and Haemostasis.

14 Feb 2011

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

Patients with strokes, brain tumors and spinal cord injuries are at high risk for life-threatening blood clots, but many do not receive preventive therapy, Loyola University Health System researchers report.

14 Feb 2011

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

Genetic testing for inherited blood-clotting abnormalities is not routinely recommended for patients with venous thromboembolism (VTE) of unknown cause, according to a new expert panel statement in a recent issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics (ACMG).

11 Feb 2011

Study: Drug-eluting stents outperform BMS for revascularization of CTOs

A systematic review of medical evidence has determined drug-eluting stents outperform bare metal stents for revascularization of chronic total occlusions.

10 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

In light of an aging population and increasing chronic vascular disease, there is a tremendous unmet need for new medical technologies to treat potentially dangerous chronic venous insufficiency (CVI) and blood clots, according to a Scientia Advisors review of the vascular device market released today. Both the CVI and the thrombosis segments present significant opportunities for medical device innovators.

3 Feb 2011

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration Biopharmaceuticals, today presented pharmacokinetic data on its lead product, IB1001, a recombinant factor IX for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Inspiration presents IB1001 PK data at European haemophilia congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

Thrombosis News and Research

Latest Thrombosis News and Research

Study: Heparin plays a key role in mast cell-driven allergic and inflammatory reactions

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Rare bleeding disorder misdiagnosed

Avesthagen completes development of microalgae based vegetarian DHA omega 3 essential fatty acid

FDA grants 510(k) clearance to Venous Health's Vasculaire Compression System in the US

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

Study: Drug-eluting stents outperform BMS for revascularization of CTOs

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

CVT more common than previously thought, disproportionally affects pregnant women

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data at European haemophilia congress

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in